Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with ...
Yahoo Malaysia

Should Harley-Davidson Build This Bike? Yes - But Also, Perhaps No

Harley-Davidson recently showed a striking, sporty and powerful concept motorcycle based on a 50-year old 'failure.' Could it ...